This is a high-impact catalyst for DSGN — first endogenous frataxin increase linked to clinical improvement in FA. Expect significant upside at open; monitor Q4 2026 registrational update for next catalyst. Risk: small sample (n=16), early-stage data may not replicate in larger trials.
Price Chart
Executive Summary
Design Therapeutics announced positive Phase 1/2 RESTORE-FA data for DT-216P2 in Friedreich ataxia, showing dose-dependent increases in frataxin mRNA and protein alongside clinical improvements (mFARS, upright stability, fatigue) after four weeks. The company plans to advance toward registrational development with an update in Q4 2026. These data represent a potential transformative catalyst for this early-stage biotech, as this is the first time endogenous frataxin increases have been linked to clinical improvements in FA patients.
Key Facts
- DT-216P2 demonstrated dose-dependent increases in frataxin mRNA (65% in whole blood, p<0.001; 42% in muscle, p=0.015) and protein (22-27% in whole blood, p<0.001) after four weeks of IV dosing at 1 mpk.
- Clinical improvements: mean 6.4-point improvement in mFARS, 2.7-point improvement in Upright Stability Score, and >5-point improvement in PROMIS Fatigue Scale (exceeding the 3-point minimal important change threshold).
- No serious adverse events or treatment discontinuations; mild-to-moderate transient ALT elevations in 3 patients (asymptomatic, on background omaveloxolone).
- Company intends to pursue registrational path with update in Q4 2026.
- Market cap ~$898M; 92% analyst bullish consensus (11 Buy, 1 Hold).
Financial Impact
Early-stage biotech with first-in-class potential in FA; positive Phase 1/2 data with biomarker and clinical proof-of-concept could drive significant revaluation. No financial data provided in release.
Risk Factors
- Small sample size (n=16) — results may not replicate in larger registrational trial.
- Transient ALT elevations, though mild, could raise regulatory scrutiny.
- Competing FA therapies (e.g., omaveloxolone) may limit commercial differentiation.
- Registrational path and timeline uncertain; Q4 update may disappoint.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3296474 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 3, 2026 12w ago | 8-K | $12.76 $15.09 | ▲ +18.26% | ▲ +17.02% | $10.41 (−18.42%) |
Aug 3, 2026 12w ago | Press Release | $12.76 $15.09 | ▲ +18.26% | ▲ +17.02% | $10.41 (−18.42%) |
May 18, 2026 23w ago | 8-K | $10.70 $10.72 | ▲ +0.19% | ▼ −1.39% | $10.41 (−2.71%) |
May 18, 2026 23w ago | Press Release | $10.70 $10.72 | ▲ +0.19% | ▼ −1.39% | $10.41 (−2.71%) |
May 17, 2026 23w ago | Press Release | $10.70 $10.72 | ▲ +0.19% | ▼ −1.39% | $10.41 (−2.71%) |
Apr 28, 2026 25w ago | Press Release | $15.79 $11.10 | ▼ −29.70% | ▼ −35.16% | $10.41 (−34.07%) |
Apr 23, 2026 26w ago | DEFA14A | $12.53 $11.01 | ▼ −12.13% | ▼ −16.16% | $10.41 (−16.92%) |
Apr 1, 2026 29w ago | 3 | $11.23 $13.60 | ▲ +21.10% | ▲ +11.23% | $10.41 (−7.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers